Profund Advisors LLC Takes Position in Evolus, Inc. $EOLS

Profund Advisors LLC purchased a new position in shares of Evolus, Inc. (NASDAQ:EOLS) during the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 10,833 shares of the company’s stock, valued at approximately $100,000.

A number of other large investors have also bought and sold shares of the stock. IFP Advisors Inc raised its holdings in Evolus by 99.0% during the 1st quarter. IFP Advisors Inc now owns 9,427 shares of the company’s stock valued at $113,000 after buying an additional 4,691 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Evolus during the first quarter valued at about $449,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Evolus during the first quarter worth about $151,000. XTX Topco Ltd bought a new stake in shares of Evolus in the first quarter worth about $742,000. Finally, Vanguard Group Inc. grew its stake in shares of Evolus by 2.0% in the first quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company’s stock worth $38,906,000 after purchasing an additional 62,664 shares during the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $7.51, for a total value of $42,972.22. Following the sale, the chief marketing officer owned 89,949 shares in the company, valued at approximately $675,516.99. This represents a 5.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on EOLS. Needham & Company LLC reiterated a “hold” rating and issued a $22.00 price objective on shares of Evolus in a report on Wednesday, August 6th. HC Wainwright decreased their target price on Evolus from $27.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolus in a report on Tuesday, November 11th. BTIG Research reissued a “buy” rating and set a $18.00 price objective on shares of Evolus in a research report on Monday, September 8th. Finally, Wall Street Zen raised shares of Evolus from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $21.25.

Evolus Stock Down 2.0%

Shares of EOLS stock opened at $7.22 on Monday. The stock has a market cap of $468.00 million, a price-to-earnings ratio of -7.85 and a beta of 0.97. The business’s fifty day moving average is $6.63 and its 200 day moving average is $8.19. Evolus, Inc. has a twelve month low of $5.71 and a twelve month high of $17.12.

Evolus (NASDAQ:EOLS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $68.97 million for the quarter, compared to analysts’ expectations of $91.23 million. Evolus had a negative net margin of 20.49% and a negative return on equity of 759.04%. Evolus has set its FY 2025 guidance at EPS. Equities research analysts expect that Evolus, Inc. will post -0.61 earnings per share for the current fiscal year.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.